Mesoblast (MESO) News Today $11.11 +0.09 (+0.82%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$11.11 0.00 (0.00%) As of 07/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Mesoblast (NASDAQ:MESO) Share Price Crosses Below 200 Day Moving Average - Here's WhyJuly 10, 2025 | marketbeat.comInsider Stock Buying Reaches US$205.4m On MesoblastJuly 8, 2025 | finance.yahoo.comMesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)July 7, 2025 | seekingalpha.comMesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?July 2, 2025 | marketbeat.comMesoblast, FDA agree on marketing application for cell therapyJuly 1, 2025 | msn.comMesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?July 1, 2025 | marketbeat.comMesoblast Targets Accelerated FDA Approval For Heart Failure Drug RevascorJuly 1, 2025 | benzinga.comMesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart FailureJune 30, 2025 | globenewswire.comMesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for RyoncilJune 29, 2025 | msn.comMesoblast (NASDAQ:MESO) Shares Down 4.2% - Here's What HappenedJune 23, 2025 | marketbeat.comMesoblast Limited (MSB.AX)June 22, 2025 | finance.yahoo.comProsperity Wealth Management Inc. Has $608,000 Stock Position in Mesoblast Limited (NASDAQ:MESO)June 18, 2025 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Shares Purchased by GAMMA Investing LLCJune 16, 2025 | marketbeat.comMesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’June 12, 2025 | msn.comMesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHDJune 11, 2025 | globenewswire.comMesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?June 11, 2025 | marketbeat.comMesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug ApprovalJune 10, 2025 | finance.yahoo.comMesoblast (NASDAQ:MESO) Trading Up 6.2% - Here's What HappenedJune 10, 2025 | marketbeat.comCantor Fitzgerald Predicts Mesoblast FY2026 EarningsJune 10, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Down - Here's What HappenedMay 30, 2025 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Shares Acquired by Bank of America Corp DEMay 29, 2025 | marketbeat.comWhich S&P 500 Move Matters?May 27, 2025 | msn.comMesoblast (NASDAQ:MESO) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?May 26, 2025 | marketbeat.comCubist Systematic Strategies LLC Has $697,000 Position in Mesoblast Limited (NASDAQ:MESO)May 18, 2025 | marketbeat.comHotCopper Highlights Week 20: Mesoblast FDA miss; Larvotto posts tungsten, Melbana & MoreMay 16, 2025 | msn.comMesoblast Limited: FDA Provides Seven Years of Orphan-Drug Exclusive Approval for RyoncilMay 15, 2025 | finanznachrichten.deIs Mesoblast Limited (MESO) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comThursday’s HotCopper trends: Mesoblast's FDA tick, Anson's green light | May 15, 2025May 15, 2025 | msn.comFDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®May 14, 2025 | globenewswire.comMesoblast Limited's (ASX:MSB) market cap dropped AU$96m last week; Individual investors bore the bruntMay 7, 2025 | finance.yahoo.comMesoblast Limited's (ASX:MSB) market cap dropped AU$96m last week; Individual investors bore the bruntMay 7, 2025 | finance.yahoo.comBullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor TrialsMay 5, 2025 | seekingalpha.comAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025April 29, 2025 | globenewswire.comMesoblast Appoints Corporate Finance Leader Lyn Cobley To BoardApril 28, 2025 | globenewswire.comMesoblast extends payer coverage for Ryoncil to over 100M U.S. livesApril 17, 2025 | markets.businessinsider.comMesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US LivesApril 16, 2025 | globenewswire.comMesoblast (NASDAQ:MESO) Shares Gap Down - Here's WhyApril 13, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Up - Still a Buy?April 10, 2025 | marketbeat.comTop broker says Mesoblast shares can rocket 100%April 7, 2025 | msn.comCantor Fitzgerald Upgrades Mesoblast (NASDAQ:MESO) to "Strong-Buy"April 5, 2025 | marketbeat.comHotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!April 4, 2025 | msn.comMesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. TariffsApril 3, 2025 | globenewswire.comFY2025 EPS Estimates for Mesoblast Cut by Cantor FitzgeraldApril 3, 2025 | marketbeat.comMesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past WeekApril 2, 2025 | finance.yahoo.comMesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart FailureApril 2, 2025 | globenewswire.comMesoblast (NASDAQ:MESO) Trading 2.9% Higher - Here's What HappenedApril 1, 2025 | marketbeat.comOaktree Fund Advisors LLC Buys Shares of 47,909 Mesoblast Limited (NASDAQ:MESO)March 31, 2025 | marketbeat.comMesoblast announces it entered into NDRA with CMS DHHS for RyoncilMarch 31, 2025 | markets.businessinsider.comOaktree Capital Management LP Takes $3.56 Million Position in Mesoblast Limited (NASDAQ:MESO)March 31, 2025 | marketbeat.com Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address MESO Media Mentions By Week MESO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MESO News Sentiment▼0.661.01▲Average Medical News Sentiment MESO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MESO Articles This Week▼44▲MESO Articles Average Week Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AXSM News Today TLX News Today CRSP News Today ADMA News Today RYTM News Today PCVX News Today AKRO News Today KRYS News Today CYTK News Today ZLAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MESO) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
